Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
General Hanamaki Hospital
Homepage:
hanamakihospital.or.jp
Alternate names:
公益財団法人総合花巻病院,
総合花巻病院
ROR:
0570csa90
OpenAlex ID:
I4405257388
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
2017
·
James F Howard
, Kimiaki Utsugisawa
, et al.
·
The Lancet Neurology
·
889
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
2021
·
James F Howard
, Vera Bril
, et al.
·
The Lancet Neurology
·
796
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
2023
·
Vera Bril
, Artur Drużdż
, et al.
·
The Lancet Neurology
·
321
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
2023
·
James F Howard
, Saskia Bresch
, et al.
·
The Lancet Neurology
·
305
Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
2019
·
Srikanth Muppidi
, Kimiaki Utsugisawa
, et al.
·
Muscle & Nerve
·
277
PDF
International clinimetric evaluation of the MG‐QOL15, resulting in slight revision and subsequent validation of the MG‐QOL15r
2016
·
Ted M. Burns
, Reza Sadjadi
, et al.
·
Muscle & Nerve
·
169
Roles of cytokines and T cells in the pathogenesis of myasthenia gravis
2020
·
A Uzawa
, S Kuwabara
, et al.
·
Clinical & Experimental Immunology
·
163
PDF
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic
2020
·
Saiju Jacob
, Srikanth Muppidi
, et al.
·
Journal of the Neurological Sciences
·
160
PDF
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
2020
·
Srikanth Muppidi
, Jeffrey T Guptill
, et al.
·
The Lancet Neurology
·
123
PDF
Three Types of Striational Antibodies in Myasthenia Gravis
2011
·
Shigeaki Suzuki
, Kimiaki Utsugisawa
, et al.
·
Autoimmune Diseases
·
105
PDF
Health‐related quality‐of‐life and treatment targets in myasthenia gravis
2014
·
Kimiaki Utsugisawa
, Shigeaki Suzuki
, et al.
·
Muscle & Nerve
·
104
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
2024
·
James F. Howard
, Vera Bril
, et al.
·
Frontiers in Neurology
·
102
The MG‐QOL15 Japanese version: Validation and associations with clinical factors
2012
·
Masayuki Masuda
, Kimiaki Utsugisawa
, et al.
·
Muscle & Nerve
·
101
The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome
2023
·
Hiroyuki Murai
, Kimiaki Utsugisawa
, et al.
·
Clinical and Experimental Neuroimmunology
·
99
Cardiac involvements in myasthenia gravis associated with anti‐ K v1.4 antibodies
2013
·
S. Suzuki
, A. Baba
, et al.
·
European Journal of Neurology
·
95
Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis
2012
·
Tomoko Masuda
, Masakatsu Motomura
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
87
PDF
Early fast‐acting treatment strategy against generalized myasthenia gravis
2016
·
Kimiaki Utsugisawa
, Yuriko Nagane
, et al.
·
Muscle & Nerve
·
83
PDF
Clinical and immunological differences between early and late-onset myasthenia gravis in Japan
2010
·
Shigeaki Suzuki
, Kimiaki Utsugisawa
, et al.
·
Journal of Neuroimmunology
·
81
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
2025
·
Richard J. Nowak
, Michael Benatar
, et al.
·
New England Journal of Medicine
·
79
Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study
2017
·
Yuriko Nagane
, Hiroyuki Murai
, et al.
·
BMJ Open
·
78
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis
2021
·
James F. Howard
, John Vissing
, et al.
·
Expert Opinion on Investigational Drugs
·
77
PDF
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)
2024
·
James F. Howard
, Tuan Vu
, et al.
·
Neurotherapeutics
·
71
PDF
Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study
2011
·
Yasushi Suzuki
, Kimiaki Utsugisawa
, et al.
·
BMJ Open
·
69
PDF
Effectiveness of 1,25-dihydroxyvitamin D Supplementation on Blood Pressure Reduction in a Pseudohypoparathyroidism Patient with High Renin Activity.
1999
·
Yasukazu KIMURA
, Minoru KAWAMURA
, et al.
·
Internal Medicine
·
64
PDF
Overlooked non-motor symptoms in myasthenia gravis
2012
·
S. Suzuki
, K. Utsugisawa
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
63
Show more works
View as search
Works count:
176
Citation count:
9,564
Year
Topic
Type
